APA (7th ed.) Citation

O'Brien, M., & Schmid-Bindert, G. (2015). Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064). European journal of cancer, 51(12), . https://doi.org/10.1016/j.ejca.2015.04.026

Chicago Style (17th ed.) Citation

O'Brien, Mary, and Gerald Schmid-Bindert. "Maintenance Pazopanib Versus Placebo in Non-Small Cell Lung Cancer Patients Non-progressive After First Line Chemotherapy: A Double Blind Randomised Phase III Study of the Lung Cancer Group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064)." European Journal of Cancer 51, no. 12 (2015). https://doi.org/10.1016/j.ejca.2015.04.026.

MLA (9th ed.) Citation

O'Brien, Mary, and Gerald Schmid-Bindert. "Maintenance Pazopanib Versus Placebo in Non-Small Cell Lung Cancer Patients Non-progressive After First Line Chemotherapy: A Double Blind Randomised Phase III Study of the Lung Cancer Group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064)." European Journal of Cancer, vol. 51, no. 12, 2015, https://doi.org/10.1016/j.ejca.2015.04.026.